Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Endo Reports Third-Quarter 2024 Financial Results and Reaffirms 2024 Financial Expectations

      (PRNewsfoto/Endo International plc)

      News provided by

      Endo, Inc.

      Nov 05, 2024, 06:45 ET

      Share this article

      Share this article


      MALVERN, Pa., Nov. 5, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), today reported financial results for the third quarter ended September 30, 2024. Endo acquired substantially all of the assets of Endo International plc ("EIP"), on April 23, 2024, as contemplated by EIP's plan of reorganization1.

      "During the quarter, Endo's XIAFLEX® franchise grew 13%, with strong performance from both the Peyronie's disease and Dupuytren's contracture indications," said Scott Hirsch, Interim Chief Executive Officer at Endo. "We continue to achieve our 2024 financial objectives, underscoring both our dedication to patients and our focus on delivering value to our stakeholders."

      ENDO THIRD-QUARTER FINANCIAL PERFORMANCE
      (in thousands)


      Successor



      Predecessor




      Three Months
      Ended
      September 30,
      2024



      Three Months
      Ended
      September 30,
      2023


      % Change

      2024 vs. 2023

      Branded Pharmaceuticals

      $         217,180



      $         203,368


      7 %

      Sterile Injectables

      $           80,128



      $           95,381


      (16) %

      Generic Pharmaceuticals

      $         110,830



      $         134,382


      (18) %

      International Pharmaceuticals

      $           18,368



      $           18,534


      (1) %

      Total Revenues, Net

      $         426,506



      $         451,665


      (6) %

      Net Loss

      $        (232,776)



      $          (28,483)


      NM

      Adjusted Net Income (a)

      $           61,963



      $         131,441


      (53) %

      Adjusted EBITDA (a)

      $         151,299



      $         143,050


      6 %







      (a)

      The information presented in the table above includes non-GAAP financial measures such as Adjusted Net Income and Adjusted EBITDA. Please refer to the "Supplemental Financial Information" section below for reconciliations of certain non-GAAP financial measures to the most directly comparable GAAP financial measures.

      1 As required by GAAP, due to the application of Fresh Start Accounting, results for the period must be presented separately for the predecessor period from January 1, 2024 through April 23, 2024 (the "Predecessor" period) and the successor nine months ended September 30, 2024 (the "Successor" period). However, to facilitate comparison of our operating results against the relevant prior periods the Company has combined the results of the Predecessor and Successor periods as non-GAAP measures ("combined" results).

      CONSOLIDATED RESULTS

      Total revenues in third-quarter 2024 were $427 million, a decrease of 6% compared to $452 million in third-quarter 2023. This decrease was primarily attributable to competitive pressure across the Generic Pharmaceuticals and Sterile Injectables segments which was partially offset by Branded Pharmaceuticals segment revenue growth.

      Net Loss in third-quarter 2024 was $233 million compared to $28 million in third-quarter 2023. This change was primarily due to the application of fresh start accounting.

      Adjusted Net Income in third-quarter 2024 was $62 million compared to $131 million in third-quarter 2023. This change was primarily due to increased interest and income tax expense in third-quarter 2024.

      Adjusted EBITDA was $151 million compared to $143 million in third-quarter 2023. This increase was primarily driven by reduced operating costs and improved adjusted gross margin, partially offset by decreased revenues.

      SEGMENT RESULTS

      Branded Pharmaceuticals segment revenues were $217 million in third-quarter 2024, a 7% increase compared to $203 million in third-quarter 2023. 

      Specialty Products revenues were $159 million in third-quarter 2024, representing a 6% increase compared to $150 million in third-quarter 2023. This increase was primarily attributable to a 13% increase in XIAFLEX® revenues to $128 million, driven by strong underlying demand and increased average net selling price. This increase was partially offset by decreased SUPPRELIN® LA revenues resulting from lower volumes and decreased NASCOBAL® Nasal Spray revenues due to discontinuation of the product.

      Established Products revenues were $58 million in third-quarter 2024, representing a 9% increase compared to $53 million in third-quarter 2023. This increase was primarily driven by royalties and certain non-recurring milestone payments related to a prior development agreement.

      Sterile Injectables segment revenues were $80 million in third-quarter 2024, a 16% decrease compared to $95 million in third-quarter 2023. This change was primarily attributable to competitive product pressures, driven by a decline in VASOSTRICT®, and temporary supply disruptions on several products that are expected to be substantially resolved by the end of 2024.

      Generic Pharmaceuticals segment revenues were $111 million in third-quarter 2024, an 18% decrease compared to $134 million in third-quarter 2023. This change was primarily attributable to competitive pressure across a number of products, driven by a decline in varenicline tablets, the generic version of Chantix®, and dexlansoprazole delayed release capsules, the generic version of Dexilant®, partially offset by increased revenues from lidocaine patch 5%, the generic version of LIDODERM®.

      International Pharmaceuticals segment revenues were $18 million in third-quarter 2024 compared to $19 million in third-quarter 2023.

      BALANCE SHEET AND LIQUIDITY

      As of September 30, 2024, Endo had approximately $368 million in unrestricted cash and cash equivalents.

      Third-quarter 2024 net cash provided by operating activities was approximately $12 million compared to approximately $131 million net cash provided by operating activities during third-quarter 2023. This change was primarily driven by the final payment of certain escrowed professional fees incurred in connection with Endo International plc's plan of reorganization, which are also reflected in the $79 million decrease in restricted cash, and increased interest and tax payments.

      In October, Endo successfully completed the repricing of its $1.5 billion senior secured term loan (the "Term Loan") due 2031. The Term Loan repricing reduces the applicable interest rate by 50 basis points to Term Secured Overnight Financing Rate plus 4.0%. There are no changes to the Term Loan maturity and all other terms and conditions remain substantially unchanged. Endo estimates that the Term Loan repricing will reduce cash interest expense by approximately $8 million annually.

      FINANCIAL EXPECTATIONS

      Based on third-quarter results and fourth-quarter expectations, Endo is affirming its Total Revenues and Adjusted EBITDA financial expectations for the full-year ending December 31, 2024. Financial expectations are inclusive of predecessor and successor periods.


      Prior Outlook


      Current Outlook

      ($ in millions)




      Total Revenues, Net

      $1,720- $1,780


      $1,720- $1,780

      Adjusted EBITDA

      $635 - $655


      $635 - $655

      Assumptions:




      Segment Revenues:




      Branded Pharmaceuticals

      $875 - $905


      $875 - $905

      Sterile Injectables

      $370 - $390


      $350- $370

      Generic Pharmaceuticals

      $410 - $420


      $430 - $440

      International Pharmaceuticals

      ~$65


      ~$65

      Adjusted Gross Margin as a Percentage of Total Revenues, Net

      ~67%


      ~67%

      Adjusted Operating Expenses

      $595 - $615


      $595 - $615

      The foregoing information includes financial guidance, expectations and other forward-looking statements based on Endo's current views, beliefs, estimates and assumptions. Actual results may differ materially and adversely from these and any other forward-looking statements, as further discussed below under the heading "Cautionary Note Regarding Forward-Looking Statements."

      PHASE 2 PLANTAR FASCIITIS STUDY UPDATE

      On October 30, 2024, Endo received results from its Phase 2 dose-ranging clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fasciitis. While study participants receiving one treatment of CCH 0.6 mg showed numerical improvement from baseline on the Pain Intensity Numeric Rating Scale (NRS) average daily pain score compared to placebo, the difference was not statistically significant.

      Though the Phase 2 study did not achieve its primary endpoint, the results were informative and, based on a post-hoc analysis, clinically meaningful for a subpopulation of patients—those with moderate to severe plantar fasciitis pain as determined by Foot Function Index subscales. Endo is continuing to evaluate the Phase 2 study data to determine next steps.

      The safety profile of CCH in the Phase 2 study was consistent with the known safety profile from other CCH clinical studies. Most adverse events were local to injection and rated as mild to moderate with no treatment-related serious adverse events.

      CONFERENCE CALL INFORMATION 

      Endo will host a conference call to discuss this press release later today, November 5, 2024, at 8:30 a.m. ET.

      To participate in the call, please dial 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (outside the U.S.) or join the live webcast at this link. Please join 10 minutes prior to the scheduled start time.

      A replay of the webcast will be available within 24 hours at investor.endo.com.

      LIDODERM® is a U.S. registered trademark of Teikoku Pharma USA, Inc.

      Dexilant® is a registered trademark of Takeda Pharmaceutical U.S.A., Inc.

      Chantix® is a registered trademark of Pfizer Inc.

      FINANCIAL SCHEDULES

      The following table presents unaudited Total revenues, net (dollars in thousands):


      Successor



      Predecessor




      Three
      Months
      Ended
      September
      30, 2024



      Three
      Months
      Ended
      September
      30, 2023


      % Change

      2024 vs. 2023

      Specialty Products:







      XIAFLEX®

      $         127,992



      $         113,053


      13 %

      SUPPRELIN® LA

      19,130



      21,590


      (11) %

      Other Specialty (1)

      12,311



      15,749


      (22) %

      Total Specialty Products

      $         159,433



      $         150,392


      6 %

      Established Products:







      PERCOCET®

      $           24,144



      $           26,290


      (8) %

      TESTOPEL®

      8,604



      9,610


      (10) %

      Other Established (2)

      24,999



      17,076


      46 %

      Total Established Products

      $           57,747



      $           52,976


      9 %

      Total Branded Pharmaceuticals (3)

      $         217,180



      $         203,368


      7 %

      Sterile Injectables:







      ADRENALIN®

      $           21,463



      $           22,873


      (6) %

      VASOSTRICT®

      15,412



      20,827


      (26) %

      Other Sterile Injectables (4)

      43,253



      51,681


      (16) %

      Total Sterile Injectables (3)

      $           80,128



      $           95,381


      (16) %

      Total Generic Pharmaceuticals (5)

      $         110,830



      $         134,382


      (18) %

      Total International Pharmaceuticals (6)

      $           18,368



      $           18,534


      (1) %

      Total Revenues, Net

      $         426,506



      $         451,665


      (6) %







      (1)

      Products included within Other Specialty include AVEED® and NASCOBAL® Nasal Spray.

      (2)

      Products included within Other Established include, but are not limited to, EDEX®.

      (3)

      Individual products presented above represent the top two performing products in each product category for either the Successor three or nine months ended September 30, 2024, the Predecessor period from January 1, 2024 through April 23, 2024 and/or any product having revenues in excess of $25 million during any quarter presented for 2024 or 2023.

      (4)

      Products included within Other Sterile Injectables include, but are not limited to, APLISOL®. No individual product within Other Sterile Injectables has exceeded 5% of consolidated total revenues for the periods presented.

      (5)

      The Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have limited or no intellectual property protection and are sold within the U.S. Lidocaine patch 5% (the generic version of LIDODERM®), made up approximately 8%, for the three months ended September 30, 2024, of consolidated revenues. During the three months ended September 30, 2023, Dexlansoprazole delayed release capsules (Endo's generic version of Takeda Pharmaceuticals USA, Inc.'s Dexilant®), which launched in November 2022, made up 7% of Predecessor consolidated total revenues.

      (6)

      No individual product within the International Pharmaceuticals segment accounted for more than 5% of consolidated total revenues for any of the periods presented.

      The following table presents the unaudited Condensed Consolidated Statement of Operations (in thousands):


      Successor



      Predecessor


      Three Months
      Ended
      September 30,
      2024



      Three Months
      Ended
      September 30,
      2023

      TOTAL REVENUES, NET

      $          426,506



      $             451,665

      COSTS AND EXPENSES:





      Cost of revenues

      448,324



      230,286

      Selling, general and administrative

      148,322



      138,772

      Research and development

      20,190



      31,582

      Acquired in-process research and development

      1,750



      —

      Litigation-related and other contingencies, net

      200



      11,104

      Acquisition-related and integration items, net

      1,773



      1,062

      Interest expense, net

      62,727



      10

      Reorganization items, net

      —



      57,960

      Other income, net

      (1,193)



      (2,217)

      LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX

      $        (255,587)



      $             (16,894)

      INCOME TAX (BENEFIT) EXPENSE

      (22,811)



      11,042

      LOSS FROM CONTINUING OPERATIONS

      $        (232,776)



      $             (27,936)

      DISCONTINUED OPERATIONS, NET OF TAX

      —



      (547)

      NET LOSS

      $        (232,776)



      $             (28,483)

      NET LOSS PER SHARE—BASIC:





      Continuing operations

      $              (3.06)



      $                 (0.12)

      Discontinued operations

      —



      —

      Basic

      $              (3.06)



      $                 (0.12)

      NET LOSS PER SHARE—DILUTED:





      Continuing operations

      $              (3.06)



      $                 (0.12)

      Discontinued operations

      —



      —

      Diluted

      $              (3.06)



      $                 (0.12)

      WEIGHTED AVERAGE SHARES:





      Basic

      76,156



      235,220

      Diluted

      76,156



      235,220

      The following table presents unaudited Total revenues, net (dollars in thousands):


      Successor



      Predecessor


      Non-GAAP


      Predecessor


      Non-GAAP


      Nine Months
      Ended
      September
      30, 2024



      Period From
      January 1,
      2024 through
      April 23,
      2024


      Combined
      Nine Months
      Ended
      September
      30, 2024


      Nine Months
      Ended
      September
      30, 2023


      % Change

      2024 vs. 2023

      Specialty Products:











      XIAFLEX®

      $         215,046



      $         152,638


      $         367,684


      $         327,254


      12 %

      SUPPRELIN® LA

      33,648



      26,213


      59,861


      73,390


      (18) %

      Other Specialty (1)

      21,651



      21,120


      42,771


      57,282


      (25) %

      Total Specialty Products

      $         270,345



      $         199,971


      $         470,316


      $         457,926


      3 %

      Established Products:











      PERCOCET®

      $           38,054



      $           33,892


      $           71,946


      $           78,791


      (9) %

      TESTOPEL®

      16,986



      13,225


      30,211


      32,199


      (6) %

      Other Established (2)

      37,947



      32,626


      70,573


      44,402


      59 %

      Total Established Products

      $           92,987



      $           79,743


      $         172,730


      $         155,392


      11 %

      Total Branded Pharmaceuticals (3)

      $         363,332



      $         279,714


      $         643,046


      $         613,318


      5 %

      Sterile Injectables:











      ADRENALIN®

      $           36,105



      $           38,601


      $           74,706


      $           75,581


      (1) %

      VASOSTRICT®

      23,338



      34,309


      57,647


      71,197


      (19) %

      Other Sterile Injectables (4)

      77,159



      59,621


      136,780


      186,886


      (27) %

      Total Sterile Injectables (3)

      $         136,602



      $         132,531


      $         269,133


      $         333,664


      (19) %

      Total Generic Pharmaceuticals (5)

      $         180,551



      $         143,677


      $         324,228


      $         511,141


      (37) %

      Total International Pharmaceuticals (6)

      $           30,184



      $           26,052


      $           56,236


      $           55,661


      1 %

      Total Revenues, Net

      $         710,669



      $         581,974


      $      1,292,643


      $      1,513,784


      (15) %







      (1)

      Products included within Other Specialty include AVEED® and NASCOBAL® Nasal Spray.

      (2)

      Products included within Other Established include, but are not limited to, EDEX®.

      (3)

      Individual products presented above represent the top two performing products in each product category for the Successor combined nine months ended September 30, 2024, the Predecessor period from January 1, 2024 through April 23, 2024 and/or any product having revenues in excess of $25 million during any quarter presented for 2024 or 2023.

      (4)

      Products included within Other Sterile Injectables include, but are not limited to, APLISOL®. No individual product within Other Sterile Injectables has exceeded 5% of consolidated total revenues for the periods presented.

      (5)

      The Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have limited or no intellectual property protection and are sold within the U.S. Lidocaine patch 5%, the generic version of LIDODERM® made up 8%, for the Successor nine months ended September 30, 2024, of consolidated revenues. Varenicline tablets (Endo's generic version of Pfizer Inc.'s Chantix®), which launched in September 2021, made up 10%, for the Predecessor nine months ended September 30, 2023 of consolidated total revenues. During the nine months ended September 30, 2023, Dexlansoprazole delayed release capsules (Endo's generic version of Takeda Pharmaceuticals USA, Inc.'s Dexilant®), which launched in November 2022, made up 6%, of Predecessor consolidated total revenues.

      (6)

      No individual product within the International Pharmaceuticals segment accounted for more than 5% of consolidated total revenues for any of the periods presented.

      The following table presents the unaudited Condensed Consolidated Statement of Operations (in thousands):


      Successor



      Predecessor


      Nine Months
      Ended
      September 30,
      2024



      Period From
      January 1, 2024
      through April 23,
      2024


      Nine Months
      Ended
      September 30,
      2023

      TOTAL REVENUES, NET

      $          710,669



      $             581,974


      $          1,513,784

      COSTS AND EXPENSES:







      Cost of revenues

      782,019



      259,552


      696,880

      Selling, general and administrative

      244,314



      158,391


      427,294

      Research and development

      42,638



      32,022


      87,322

      Acquired in-process research and development

      1,750



      750


      —

      Litigation-related and other contingencies, net

      200



      200


      54,317

      Asset impairment charges

      —



      2,103


      146

      Acquisition-related and integration items, net

      1,643



      (196)


      1,824

      Interest expense (income), net

      107,396



      (2)


      239

      Reorganization items, net

      —



      (6,125,099)


      227,579

      Other (income) expense, net

      (947)



      5,262


      (2,163)

      (LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAX

      $        (468,344)



      $          6,248,991


      $               20,346

      INCOME TAX (BENEFIT) EXPENSE

      (86,792)



      58,511


      27,094

      (LOSS) INCOME FROM CONTINUING OPERATIONS

      $        (381,552)



      $          6,190,480


      $               (6,748)

      DISCONTINUED OPERATIONS, NET OF TAX

      —



      182,838


      (1,576)

      NET (LOSS) INCOME

      $        (381,552)



      $          6,373,318


      $               (8,324)

      NET (LOSS) INCOME PER SHARE—BASIC:







      Continuing operations

      $              (5.01)



      $                 26.32


      $                 (0.03)

      Discontinued operations

      —



      0.78


      (0.01)

      Basic

      $              (5.01)



      $                 27.10


      $                 (0.04)

      NET (LOSS) INCOME PER SHARE—DILUTED:







      Continuing operations

      $              (5.01)



      $                 26.32


      $                 (0.03)

      Discontinued operations

      —



      0.78


      (0.01)

      Diluted

      $              (5.01)



      $                 27.10


      $                 (0.04)

      WEIGHTED AVERAGE SHARES:







      Basic

      76,156



      235,220


      235,219

      Diluted

      76,156



      235,220


      235,219

      The following table presents the unaudited Condensed Consolidated Balance Sheet (in thousands):


      Successor



      Predecessor


      September 30,
      2024



      December 31,
      2023

      ASSETS





      CURRENT ASSETS:





      Cash and cash equivalents

      $       367,574



      $         777,919

      Restricted cash and cash equivalents

      87,492



      167,702

      Accounts receivable

      383,225



      386,919

      Inventories, net

      613,275



      246,017

      Other current assets

      75,197



      89,944

        Total current assets

      $     1,526,763



      $      1,668,501

      TOTAL NON-CURRENT ASSETS

      3,152,937



      3,468,793

      TOTAL ASSETS

      $     4,679,700



      $      5,137,294

      LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)





      CURRENT LIABILITIES:





      Accounts payable and accrued expenses, including legal settlement accruals

      $        486,510



      $         537,736

      Other current liabilities

      60,234



      1,058

        Total current liabilities

      $        546,744



      $         538,794

      LONG-TERM DEBT, LESS CURRENT PORTION, NET

      2,424,439



      —

      OTHER LIABILITIES

      107,962



      100,192

      LIABILITIES SUBJECT TO COMPROMISE

      —



      11,095,868

      SHAREHOLDERS' EQUITY (DEFICIT)

      1,600,555



      (6,597,560)

      TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)

      $     4,679,700



      $      5,137,294

      The following table presents the unaudited Condensed Consolidated Statement of Cash Flow data (in thousands):


      Successor



      Predecessor


      Nine Months
      Ended
      September 30,
      2024



      Period From
      January 1, 2024
      through April 23,
      2024


      Nine Months
      Ended
      September 30,
      2023

      OPERATING ACTIVITIES:







      Net (loss) income

      $           (381,552)



      $          6,373,318


      $               (8,324)

      Adjustments to reconcile Net (loss) income to Net cash provided by (used in) operating
      activities

      465,038



      (7,117,959)


      328,365

        Net cash provided by (used in) operating activities

      $               83,486



      $            (744,641)


      $             320,041

      INVESTING ACTIVITIES:







      Capital expenditures, excluding capitalized interest

      (22,209)



      (19,751)


      (74,245)

      Acquisitions, including in-process research and development, net of cash and restricted
      cash acquired

      (1,750)



      (750)


      —

      Proceeds from sale of business and other assets

      3,685



      2,188


      3,538

      Proceeds from the U.S. Government Agreement

      1,034



      7,728


      32,560

        Net cash used in investing activities

      $             (19,240)



      $              (10,585)


      $             (38,147)

      FINANCING ACTIVITIES:







      Payments on borrowings, including certain adequate protection payments, net (a)

      —



      (2,783,950)


      (445,519)

      Proceeds from issuance of debt and equity, net of other payments

      (7,072)



      2,907,558


      (9,352)

        Net cash (used in) provided by financing activities

      $               (7,072)



      $             123,608


      $           (454,871)

      Effect of foreign exchange rate

      887



      (1,998)


      (20)

      NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, RESTRICTED CASH
      AND RESTRICTED CASH EQUIVALENTS

      $               58,061



      $            (633,616)


      $           (172,997)

      CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH
      EQUIVALENTS, BEGINNING OF PERIOD

      397,005



      1,030,621


      1,249,241

      CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH
      EQUIVALENTS, END OF PERIOD

      $             455,066



      $             397,005


      $          1,076,244







      (a)

      Beginning during the third quarter of 2022, Endo International plc (EIP) became obligated to make certain adequate protection payments as a result of its previously disclosed Chapter 11 proceedings.

      SUPPLEMENTAL FINANCIAL INFORMATION

      Non-GAAP Financial Measures

      To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company provides certain financial information of Endo, Inc. in this release that are not prescribed by or prepared in accordance with GAAP. The Company utilizes these non-GAAP financial measures as supplements to financial measures determined in accordance with GAAP when evaluating operating performance and the Company believes that these measures will be used by certain investors to evaluate operating results. The Company believes that presenting these non-GAAP financial measures provides useful information about performance across reporting periods on a consistent basis by excluding certain items, which may be favorable or unfavorable, as more fully described in the reconciliation tables below.

      Despite the importance of these measures to management in goal setting and performance measurement, the Company stresses that these are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted EBITDA and non-GAAP adjusted net income (unlike GAAP net income and its components) may differ from, and may not be comparable to, the calculation of similar measures of other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses performance. 

      These non-GAAP financial measures should not be viewed in isolation or as substitutes for, or superior to, financial measures calculated in accordance with GAAP.  Investors are encouraged to review the reconciliations of the non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures. However, the Company does not provide reconciliations of projected non-GAAP financial measures to GAAP financial measures, nor does it provide comparable projected GAAP financial measures for such projected non-GAAP financial measures. The Company is unable to provide such reconciliations without unreasonable efforts due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for asset impairments, contingent consideration adjustments, legal settlements, gain / loss on extinguishment of debt, adjustments to inventory and other charges reflected in the reconciliation of historic numbers, the amounts of which could be significant.

      The tables below provide reconciliations of certain of the non-GAAP financial measures included in this release to their most directly comparable GAAP metrics. Refer to the "Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures" section below for additional details regarding the adjustments to the non-GAAP financial measures detailed throughout this Supplemental Financial Information section.

      Reconciliation of Net Loss (GAAP) to EBITDA (non-GAAP) and Adjusted EBITDA (non-GAAP)

      The following table provides a reconciliation of Net Loss (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands):


      Successor



      Predecessor (a)


      Three Months
      Ended
      September 30,
      2024



      Three Months
      Ended
      September 30,
      2023

      Net Loss (GAAP)

      $      (232,776)



      $          (28,483)

      Income tax (benefit) expense, net

      (22,812)



      11,042

      Interest expense, net

      62,727



      10

      Depreciation and amortization (1)

      75,562



      77,087

      EBITDA (non-GAAP)

      $      (117,299)



      $           59,656

      Acquisition & Divestitures (2)

      263,084



      1,062

      Restructuring or similar transactions (3)

      6,507



      10,764

      Reorganization items, net (4)

      —



      57,960

      Other (5)

      (993)



      13,061

      Discontinued Operations (7)

      —



      547

      Adjusted EBITDA (non-GAAP)

      $       151,299



      $         143,050







      (a)

      Certain prior period non-GAAP adjustments have been reclassified to conform to the current period presentation. Unless otherwise noted in the footnotes below, there have been no changes to the adjustment amounts.

      Reconciliation of Net Loss (GAAP) to Adjusted Net Income (non-GAAP)

      The following table provides a reconciliation of Endo's Net Loss (GAAP) to Adjusted Net Income (non-GAAP) (in thousands):


      Successor



      Predecessor (a)


      Three Months
      Ended
      September 30,
      2024



      Three Months
      Ended
      September 30,
      2023

      Net Loss (GAAP)

      $      (232,776)



      $          (28,483)

      Non-GAAP adjustments:





      Acquisition & Divestitures (2)

      324,452



      65,616

      Restructuring or similar transactions (3)

      6,507



      10,764

      Reorganization items, net (4)

      —



      57,960

      Other (5)

      (993)



      12,949

      Tax adjustments (6)

      (35,227)



      12,088

      Discontinued Operations (7)

      —



      547

      Adjusted Net Income (non-GAAP)

      $         61,963



      $         131,441







      (a)

      Certain prior period non-GAAP adjustments have been reclassified to conform to the current period presentation. Unless otherwise noted in the footnotes below, there have been no changes to the adjustment amounts.

      Reconciliation of Select Other Adjusted Income Statement Data (non-GAAP)

      The following tables provide detailed reconciliations of select other income statement data for Endo, Inc. between the GAAP and non-GAAP measure (in thousands):



      Three Months Ended September 30, 2024 (Successor)



      Cost of
      revenues


      Gross profit (a)


      Gross margin
      (a)


      Total operating
      expenses (b)


      Reorganization
      items, net


      Other (income)
      expense, net


      Income tax
      (benefit)
      expense

      Reported (GAAP)


      $        448,324


      $        (21,818)


      (5.1) %


      $        172,235


      $                —


      $        (1,193)


      $        (22,811)

      Items impacting comparability:















      Acquisition & Divestitures
      (2)


      (309,397)


      309,397




      (15,054)


      —


      —


      —

      Restructuring or similar
      transactions (3)


      (74)


      74




      (6,433)


      —


      —


      —

      Other (5)


      —


      —




      (200)


      —


      1,193


      —

      Tax adjustments (6)


      —


      —




      —


      —


      —


      35,227

      Non-GAAP


      $        138,853


      $        287,653


      67.4 %


      $        150,548


      $                —


      $              —


      $         12,416




      Three Months Ended September 30, 2023 (c)



      Cost of
      revenues


      Gross profit (a)


      Gross margin
      (a)


      Total operating
      expenses (b)


      Reorganization
      items, net


      Other income,
      net


      Income tax
      expense
      (benefit)

      Reported (GAAP)


      $        451,665


      $        221,379


      49.0 %


      $         182,520


      $         57,960


      $        (2,217)


      $         11,042

      Items impacting
      comparability:















      Acquisition & Divestitures 
      (2)


      (64,554)


      64,554




      (1,062)


      —


      —


      —

      Restructuring or similar
      transactions (3)


      (1,342)


      1,342




      (9,422)


      —


      —


      —

      Reorganization items, net
      (4)


      —


      —




      —


      (57,960)


      —


      —

      Other (5)


      —


      —




      (15,152)


      —


      2,203


      —

      Tax adjustments (6)


      —


      —




      —


      —


      —


      (12,088)

      Non-GAAP


      $        385,769


      $        287,275


      63.6 %


      $         156,884


      $                —


      $             (14)


      $          (1,046)







      (a) 

      Gross profit is calculated as total revenues less cost of revenues. Gross margin is calculated as gross profit divided by total revenues. Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.

      (b)

      Total operating expenses is calculated as the total of: (i) Selling, general and administrative; (ii) Research and development; (iii) Acquired in-process research and development; (iv) Litigation-related and other contingencies, net; (v) Asset impairment charges; and (vi) Acquisition related and integration items, net.

      (c)

      Certain prior period non-GAAP adjustments have been reclassified to conform to the current period presentation. Unless otherwise noted in the footnotes below, there have been no changes to the adjustment amounts.

      Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures

      Notes to certain line items included in the reconciliations of the GAAP financial measures to the non-GAAP financial measures are as follows:


      (1)

      Depreciation and amortization per the Adjusted EBITDA reconciliations do not include amounts reflected in other lines of the reconciliations, including amounts related to restructuring or other transactions.



      (2)

      Adjustments for acquisitions and divestitures included the following (in thousands):




      Successor



      Predecessor


      Three Months Ended
      September 30, 2024



      Three Months Ended
      September 30, 2023


      Cost of
      revenues


      Operating
      expenses



      Cost of
      revenues


      Operating
      expenses

      Amortization of inventory step-up

      $      248,029


      $               —



      $               —


      $               —

      Fair value of contingent consideration

      —


      1,773



      —


      1,062

      Amortization of intangible assets (a)

      61,368


      —



      64,429


      —

      Integration

      —


      13,281



      —


      —

      Other acquisition and divestiture items

      —


      —



      125


      —

      Total

      $      309,397


      $       15,054



      $        64,554


      $          1,062







      (a)

      For the purposes of calculating Adjusted EBITDA (non-GAAP), amortization of intangible assets is excluded from the adjustments for acquisitions and divestitures as it is included as an adjustment to arrive at EBITDA (non-GAAP). Amortization of intangible assets is an adjustment included in the acquisitions and divestitures line item for the purposes calculating Adjusted Net Income (non-GAAP).



      (3)

      Adjustments for Restructuring or similar transactions included the following (in thousands):




      Successor



      Predecessor


      Three Months Ended September 30,

      2024



      Three Months Ended September 30,

      2023


      Cost of revenues


      Operating
      expenses



      Cost of revenues


      Operating
      expenses

      Continuity and separation benefits

      $                    —


      $               6,433



      $               1,000


      $               9,424

      Inventory adjustments

      —


      —



      342


      (2)

      Other

      74


      —



      —


      —

      Total

      $                    74


      $               6,433



      $               1,342


      $               9,422







      (4)

      Amounts relate to the net expense or income recognized during Endo International plc's bankruptcy proceedings required to be presented as Reorganization items, net under Accounting Standards Codification Topic 852, Reorganizations.



      (5)

      The "Other" row included in the above reconciliation of Net (Loss) Income (GAAP) to Adjusted Net Income (non-GAAP) includes the following adjustments:




      Successor



      Predecessor


      Three Months
      Ended September
      30, 2024



      Three Months Ended September 30, 2023


      Other (Income)/

      Expense



      Operating
      expenses


      Other
      (Income)/

      Expense


      Discontinued
      Operations

      Certain Legal Costs

      $              (280)



      $         (1,514)


      $                —


      $                —

      Legal Settlements

      —



      (11,104)


      —


      —

      Foreign currency impact related to the re-measurement of intercompany
      debt instruments

      (601)



      —


      2,203


      —

      Other

      (312)



      (2,534)


      —


      (547)

      Total

      $            (1,193)



      $       (15,152)


      $           2,203


      $            (547)







      (6)

      Adjusted income taxes are calculated by tax effecting adjusted pre-tax income and permanent book-tax differences at the applicable effective tax rate that will be determined by reference to statutory tax rates in the relevant jurisdictions in which Endo, Inc. or EIP operates. Adjusted income taxes include current and deferred income tax expense commensurate with the non-GAAP measure of profitability.



      (7)

      To exclude from the results of the Predecessor reported as discontinued operations. No portion of Endo, Inc.'s business is currently reported as a discontinued operation.

      About Endo

      Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

      Cautionary Note Regarding Forward-Looking Statements

      This press release contains forward-looking statements including, but not limited to the statements by Mr. Hirsch and any statements relating to supply disruptions, pipeline development, financial guidance, expectations, plans or projections and any other statements that refer to expected, estimated, predicted or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are examples of forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: the effects of the emergence of EIP's operating assets from the Chapter 11 financial restructuring process, including as it relates to the accounting for the effects of the Plan and the application of fresh start accounting; changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition such as those related to XIAFLEX®; the timing and uncertainty of the results of both the research and development and regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation; the performance including the approval, introduction and consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; our ability to develop and expand our product pipeline and to launch new products and to continue to develop the market for XIAFLEX® and other branded, sterile injectable or unbranded products; the effectiveness of advertising and other promotional campaigns; and the timely and successful implementation of business development opportunities and/or any other strategic priorities. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.

      Copies of the Company's press releases and additional information about the Company are available at www.endo.com or you can contact the Company's Investor Relations Department at [email protected].

      SOURCE Endo, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.